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In Brief
Although glucocorticoids are widely used anti-inflammatory drugs, relevant mechanisms are unclear. Oh et al. monitored the epigenomic landscape of macrophages and found that the geneinducing activity of GR is crucial for boosting inhibitors of inflammatory factors. This cautions the idea that GR ligands selectively promoting transrepression should improve therapeutic outcome.
INTRODUCTION
Macrophages are critical effector cells of the innate immune system and they can take on diverse homeostatic or pathological roles through context-dependent differentiation (Gosselin et al., 2014; Wynn et al., 2013) . Macrophages have a direct role in numerous tissue-damaging inflammatory conditions including Alzheimer's disease, atherosclerosis, inflammatory bowel disease, and stroke. Uncontrolled macrophage activation can lead to secretion of pro-inflammatory cytokines such as TNF-a and IL-1b, induction of nitric oxide (NO) synthase, further in vivo recruitment of other immune cells, and/or activation of adaptive immune cells via antigen presentation or cytokinemediated polarization. Even for diseases where macrophages might not have a causal role, therapeutic interventions impact macrophages because of their ubiquitous presence throughout the body.
Glucocorticoids (GCs) are the most widely prescribed anti-inflammatory drugs to treat numerous inflammatory conditions ranging from asthma to psoriasis (Gerstein et al., 2012) . GCs exert their therapeutic effects primarily through the glucocorticoid receptor (GR). The generally accepted mechanism is that GR antagonizes chromatin interactions of transcription factors such as NF-kB by tethering to these DNA-bound pro-inflammatory factors and recruiting co-repressors, resulting in subsequent trans-repression of TNF-a and other inflammatory genes (Reichardt et al., 2001) . Global effects of a synthetic GR ligand Dexamethasone (Dex) have been studied in cells treated with Dex prior to or together with an inflammatory stimulus (Rao et al., 2011; Uhlenhaut et al., 2013) . However, the clinical use of GCs is to treat inflammatory conditions whereby the GC targets pathologically active immune cells, not quiescent immune cells.
Hence, missing from the extensive literature on GCs and GR biology is a characterization of the genomic action of GR in immune cells that have already received an inflammatory signal. Because there is clear evidence that the chromatinscape is a dynamic entity that is shaped by cell differentiation and external stimuli (Ghisletti et al., 2010; Gosselin et al., 2014; He et al., 2012; Heinz et al., 2010; John et al., 2011; Siersbaek et al., 2011; Thurman et al., 2012) , such a gap in our knowledge raises several questions. Are the transcription factors in a race for gene regulation, wherein the first transcription factors (TFs) to arrive on the regulatory site dominate over the late-arriving TFs? Does the repertoire of GR binding sites depend on the timing of activation with respect to the onset of inflammation? If so, how is the binding repertoire related to GR action? To address these unresolved questions, we examined the epigenomic and transcriptomic responses of primary macrophages, varying the order of GC treatment with respect to the onset of an inflammatory signal.
RESULTS

Primary Macrophages Treated with Dex Before or After an Inflammatory Stimulus Share a Global Transcriptional Profile
We investigated three different courses of lipopolysaccharide (LPS) responses in mouse bone-marrow-derived macrophages (BMDMs): a reference time course after LPS stimulation alone without Dex, another time course treated early with Dex (before LPS stimulation), and another course treated late with Dex (after LPS) ( Figure 1A ). RNA-seq was performed in biological duplicates to profile the transcriptome at 4 hr and 10 hr after LPS stimulation, except for the late Dex-treated course where sample collection is feasible only for the 10 hr LPS time point. We assessed how the expression of LPS-regulated genes is altered by Dex, treated early or late with respect to the onset of LPS stimulation. Both early and late treatments of Dex reversed the LPS-induced transcriptional regulation of a large number of genes, with the early Dex treatment producing higher magnitude effects ( Figure 1B , Figure S1 ). Because global scatterplots only allow pairwise comparisons of individual conditions, we performed an unsupervised cluster analysis to discover distinct expression patterns across all the conditions. We utilized a robust variant of the widely used K-means algorithm, varying the number of clusters, and applied the clustering method to the set of LPS-induced genes (1,820 in total according to our criteria; see STAR Methods) ( Figure 2A ) (Table S1 ). The analysis revealed three major clusters of LPS-induced genes (Clusters 1-3). Cluster 1 contained genes whose expression is reduced by Dex, largely independent of the timing of Dex. Genes in cluster 2 and 3 were less affected by Dex and distinguishable by the magnitude of LPS-induced fold change in expression.
Select Genes Are Differentially Regulated by Dex Based On the Timing of Treatment
We noted that the cluster analysis did not detect a class of genes whose expression differed between the two Dex treatments of interest in our study. Unsupervised cluster analysis can miss subtle patterns in a small number of genes if they are obscured by other large-amplitude effects. Therefore, we focused on the two conditions, directly comparing the early and late Dex treatments. 102 genes (referred to as the class ''lower in late Dex'') were indeed found to have a higher expression in the early versus late Dex (Table S2) , potentially corresponding to genes that Dex may suppress more efficiently when given with a clinically relevant timing. On the other hand, 319 genes were expressed at lower amounts in the early versus late (referred to as ''lower in early Dex'') ( Table S3 (B) Genome-wide expression patterns from RNA-seq data. Scatterplots show mean log2 (FPKM + 0.1) values from biological duplicates. The red and blue points mark highly induced and repressed genes, respectively, i.e., genes with fold change greater than 4 for at least one post-LPS time point. The pink and sky blue points mark modestly induced and repressed genes, respectively, i.e., those with fold change between 2 and 4 for at least one post-LPS time point. The black points show the remaining genes. Green dashed line indicates the diagonal. The color coding of genes is the same for all the plots to keep track of the LPSregulated genes in plots comparing Dex-treated and Dex-untreated samples. See also Figure S1 .
genes from each class was confirmed by RT-qPCR ( Figure S2 ). Gene ontology analysis revealed a striking separation of these two classes: the ''lower in late Dex'' class was enriched for genes regulating various aspects of metabolism, while the ''lower in early Dex'' class showed enrichment for immune genes including those encoding cytokines, chemokines, and their receptors ( Figure 2B , Tables S4 and S5 ). The ''lower in late Dex'' class contained several genes with essential roles in inflammatory conditions, including Cx3cr1, Selp, Cd55, Cxcl13, Clec5a , and Pstpip1. However, their functional categories did not show up in our gene ontogeny (GO) analysis, because these genes were outnumbered by the metabolism-related genes in our GO analysis. Despite the limited number, there is abundant evidence that these genes are mechanistically implicated in inflammatory diseases. For example, Cx3cr1 (encoding fractalkine receptor) is a useful surface marker of tissue resident macrophages distinguishing them from infiltrating monocyte-derived macrophages (Mizutani et al., 2012) . P-selectin, encoded by Selp, mediates neutrophil adhesion to endothelium (Woollard et al., 2008) and has been reported to exacerbate inflammatory vascular diseases (Kisucka et al., 2009 ). CXCL13 is a chemokine that recruits T and B lymphocytes to inflamed tissues, which can promote the formation of ectopic germinal centers (Hui et al., 2015; Weiss et al., 2016) . Clec5a encodes C-type lectin domain family 5, member A (also known as myeloid DNAX activation protein 12-associating lectin-1), which is a cell surface receptor specifically expressed in TNF-a producing inflammatory macrophages (Gonzá lez- Domí-nguez et al., 2015) . Activation of CLEC5A, such as by direct binding of dengue virus, leads to TNF-a and NO production in myeloid cells, which induces lethal shock (Chen et al., 2008; Cheung et al., 2011) . Several mutations in Pstpip1 have been implicated in the pathogenesis of autoinflammatory pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA) (Smith et al., 2010; Wise et al., 2002; Zeeli et al., 2015) , and the mutant proteins bind to components of the inflammasome, causing constitutive assembly and activation of the complex (Shoham et al., 2003; Yu et al., 2007) . In summary, our analysis reveals a small cohort of highly inflammatory genes among those that are apparently controlled more effectively by a late Dex treatment (in the LPS-activated macrophages) in comparison to Dex given early. 
GR Activation Globally Inhibits Genomic Occupancy of NF-kB
To understand the gene regulatory outcomes in terms of molecular events occurring in chromatin, we mapped the occupancy of RelA, the transcriptionally active subunit of NF-kB classical dimer in BMDMs. The various treatment schedules were essentially the same as for RNA-seq, while the chromatin samples were collected at slightly earlier time points (0, 3, 8 hr after LPS) (Figure S3A ). The binding patterns of NF-kB in response to LPS showed expected stimulus-dependent recruitment to promoters and distal binding sites ( Figures 3A-3C , Figure S3B ). Peak binding of RelA was observed 3 hr after LPS (4,533 binding sites in total), presumably because the nuclear influx and binding of NF-kB is synchronous immediately after LPS stimulation. This is also consistent with the heterogeneous nuclear occupancy of NFkB in the late stage of LPS response across the population at the single cell level (Lee et al., 2009; Sung et al., 2014b) . According to the widely discussed model of GR transrepression, GR binds in close proximity or tethered to chromatin-bound NF-kB or AP-1 and interferes with their activity (Chinenov et al., 2012; Reichardt et al., 2001 wide occupancy of NF-kB would then remain largely unchanged after GR activation. Contrary to this expectation, the RelA ChIP-seq analysis of Dex-treated BMDMs showed a global reduction of NF-kB binding in the genome, regardless of the timing of Dex treatment ( Figure 3D , Figure S3B ). Moreover, the disruption of RelA binding was observed not only for Dex-repressed genes but also for Dex-insensitive genes. The observed widespread decrease of NF-kB binding could be due to disruption of chromatin interaction or lower concentrations of NF-kB in the nucleus. To distinguish between the two possibilities, we performed live cell imaging of EGFP-RelA RAW264.7 reporter clonal cell line (Sung et al., 2014b) under identical treatment conditions. Applying previously developed quantitative image analyses, we generated single cell real time dynamics data and obtained similar nuclear RelA dynamics. There was only a slight reduction of nuclear RelA occupancy in Dex pre-treated cells ( Figures S4A-S4C ). This is consistent with the most dramatic reduction of RelA ChIP-seq density from Dex pre-treatment of BMDM. However, there were little or no defect in terms of upstream signaling activities or nuclear RelA amounts in Dex-treated BMDMs as observed by immunoblot ( Figures S4D and S4E ), which supports that signaling strength or nuclear abundance do not explain the lack of RelA chromatin occupancy in Dex treated BMDMs. A technical caveat that might have contributed to the reduced RelA ChIP-seq intensity is potential epitope inaccessibility in RelA when bound to GR. However, this seems unlikely, because the polyclonal antibody targets the C terminus of RelA, and the GR binding is through the N-terminal Rel homology domain (McKay and Cidlowski, 2000) .
When the distributions of NF-kB binding sites near LPSinduced genes were analyzed for each gene cluster, the Dex-transrepressed gene cluster contained genes that were normally bound by NF-kB at fewer sites ( Figure 3E , ''LPSinduced_1''). The observation suggests that these genes are readily perturbed by GR, perhaps because of their critical dependence on the relatively small number of enhancers through which NF-kB exerts its regulatory actions. It is possible that the genes with numerous RelA sites might still be subject to NF-kB regulation even when GR disables a few of their NF-kB responsive enhancers.
Genomic Occupancy of GR Is Greatly Enhanced in LPSActivated Macrophages, Regardless of Gene Regulatory Outcome Given the shared and differential features of gene regulation from the differently timed Dex treatment, we asked whether they can be explained by GR binding patterns. GR ChIP-seq was performed for two samples: BMDMs treated with Dex for 3 hr (without LPS) and BMDMs activated by LPS with late Dex treatment (3 hr after LPS) ( Figure S3A ). The comparison of ChIP-seq profiles from Dex alone versus late-treatment after LPS revealed that the late treatment of Dex produced a dramatically enhanced binding of GR ( Figures 4A-4C ), even though most Dex-sensitive genes were strongly repressed by the early Dex treatment. When GR was activated after LPS stimulation, it was able to bind to nearly eight thousand new sites in addition to about a thousand sites bound by GR when activated before LPS. The vast majority of GR sites from Dex alone were also bound by GR when it was activated after LPS (1,191/1,391) ( Figure 4C and Figure S6 ).
The result that GR binds to such a small number of sites (1,391 in the absence of LPS) with mostly weak ChIP signal 3 hr after Dex treatment was unexpected, because Dex is a ligand that binds and activates GR directly without going through any signal transduction pathways. This finding is in stark contrast to previous reports where strong GR binding is observed often within 1 hr in many cell types Reddy et al., 2009 ). Because we obtained genome-wide GR ChIP-seq data at one time point following Dex treatment, we cannot exclude the possibility that peak GR binding is achieved at earlier times. However, that scenario seems unlikely because we have confirmed by ChIP-qPCR that no GR binding is detected for earlier time points after Dex treatment alone at a GR target locus Lcn2 in BMDMs ( Figure S6A ).
We then sought to understand how LPS-activated macrophages gain the additional GR binding sites. A motif discovery analysis was performed using the MEME suite of tools to identify features of DNA sequences at the sites that GR could not bind with Dex alone but required LPS for binding. A motif for PU.1, a transcription factor essential for myeloid differentiation, as well as the expected canonical GR response element (GRE) motif, was enriched in sites that were bound by GR regardless of LPS. In particular, a slightly degenerate form of this motif was found in virtually all GR sites that were gained after LPS stimulation. Our differential motif analysis showed that the GR binding sites which appeared after LPS stimulation were preferentially enriched for a NF-kB (RelA) motif ( Figure S6B ). These findings are consistent with the view that GR mainly targets the enhancers shaped by the lineage factor PU.1 in resting macrophages, and this limited repertoire of GR binding sites is expanded through loading mechanisms assisted by LPS-activated factors such as NF-kB and AP-1 Miranda et al., 2013; Voss et al., 2011) . RelA might not be solely responsible for direct recruitment of GR to these de novo sites, because only 17% of the de novo GR sites were co-localized with RelA binding sites (observed from ChIP-seq at 3 hr after LPS stimulation). However, the de novo GR sites were preferentially located in the vicinity of RelA binding sites (median distance: 35 kb, Figure 4D ). These results suggest that GR binding might be enhanced after NF-kB and other LPS-activated factors alter the chromatinscape not only directly at potential GR binding sites but also possibly via a long-range mechanism involving higher-order structures.
Next we asked whether the GR binding sites found specifically near Dex-sensitive genes conformed to this globally enhanced occupancy or exhibit distinct behaviors that explain the effects of GR on these LPS-induced targets. To address this question, we employed two approaches. First, we compared the occurrences of GR binding sites near the gene classes that we obtained from RNA-seq ( Figure 4E ). Even though the first class (''LPS-induced_1'') was the most sensitive to Dex, these genes tend to harbor about the same number of, or even fewer, GR binding sites in comparison to those in the other classes. The second method was to look for a subtle relationship without grouping genes or sites using an algorithm. We integrated the Dex-related expression data values from RNA-seq and GR ChIP-seq signal intensity of nearby binding sites, and did not observe any relationship between GR binding and its gene regulatory effects ( Figure S6C ). For example, both Serpine1 and Ccr7 were more effectively suppressed by Dex pre-treatment versus late treatment, but showed minimal GR binding with Dex alone and greatly enhanced GR binding in BMDMs activated by LPS and subsequently treated with Dex ( Figures  4A and 4B) . From these results, we conclude that the genomic distribution of GR binding sites does not explain the genespecific regulatory activity of GR in macrophages.
GR Activation Results in Modest Local Modulation of Chromatin Accessibility
The binding patterns described above underscore the idea that the genomic occupancy of NF-kB and GR might not fully report the changes impressed upon the macrophage epigenome by Dex and LPS. Thus we probed chromatin accessibility, a proxy for regulatory activity, by performing DNase-seq on BMDMs 8 hr after LPS under the three conditions: without Dex, pretreated with Dex, and late-treated with Dex. After confirming the reproducibility of DNase-seq intensity profiles across biological replicates ( Figure S7A ), we compared chromatin accessibility across the conditions for DHSs near LPS-induced genes in the clusters identified earlier. Klf6 belongs to the Dex-sensitive cluster 1 with numerous promoter-proximal and distal DHSs. Most of these DHSs showed reduced accessibility to some extent in Dex-treated BMDMs ( Figure 5A, solid boxes) . However, even the Dex-insensitive DHSs coincided with GR binding near Klf6 and many other loci ( Figures 5A-5D , dashed boxes), ruling out a simple correlation between GR occupancy and Dex effects upon chromatin. In fact, we found no globally noticeable Dex-dependent changes in chromatin accessibility at GR bound regions ( Figure S7B ). Moreover, relatively Dex-resistant genes Il12b (cluster 2) and Clec5a (cluster 3) also had both Dex-suppressed DHSs and Dex-insensitive DHSs ( Figures 5C  and 5D ).
To determine whether there exists any link between gene regulation and chromatin behavior, we compared genomewide DNase-seq intensity profiles of Dex pre-treated (or latetreated) versus Dex untreated BMDMs. Overall, the chromatin accessibility was largely unchanged, especially for promoter DHSs ( Figure 5E, black points) . However, when (non-promoter) DHSs within 10 kb of LPS-induced genes were labeled according to the Dex effects upon the expression of these genes, a subtle pattern emerged: DHSs near Dex-suppressed genes have reduced accessibility from Dex treatment ( Figure 5E , red to orange points). On the other hand, distal DHSs near Dex-enhanced genes had increased accessibility from Dex treatment ( Figure 5E , yellow to green points). Notably, this genome-wide pattern was shared by both Dex pre-and Dex late-treated BMDMs (Figure 6 ). These results indicate that, despite the variable distribution of DHSs and their heterogeneous behaviors in Dex-treated BMDMs, the regulatory sites near the strongly Dex-regulated genes tend to exhibit the corresponding regulation of chromatin accessibility in the same direction. ). (E) Occurrences of GR binding near genes grouped by the clusters from RNA-seq analysis. Violin plots show the number of post-LPS GR ChIP-seq sites within 20 kb of TSS for genes in the indicated clusters or subsets. The violin plots were generated in the same manner as in Figure 3E . The ''Dex-regulated'' set consists of genes which were expressed independently of LPS but differentially regulated by Dex. See also Figures S3, S5 , and S6. 
GR Trans-Activates Inhibitors of Inflammatory Factors
The lack of correlation between GR binding and chromatin accessibility ( Figures 5A-5D and Figure S7B ) motivated us to consider secondary non-chromatin mechanisms that contribute to the anti-inflammatory effects of GC. In addition to suppressing numerous inflammation-associated genes, GR transcriptionally activates many genes that encode negative regulators of inflammatory factors (H€ ubner et al., 2015) . Among the highly Dex-induced genes from our RNA-seq analysis were such examples as Nfkbia (encoding IkBa), Tnfaip3 (encoding A20), Dusp1 and Dusp6 (encoding dual specificity phosphatases, DUSPs), and Tsd22d3 (encoding glucocorticoid-induced leucine zipper, GILZ). The negative feedback regulator IkBa of NF-kB binds directly to NF-kB dimers and depletes them from the nucleus by constant nucleocytoplasmic shuttling and preferential localization in the cytoplasm. A20 is a dual-function ubiquitin-editing enzyme. On the one hand, its de-ubiquitinase domain removes activating K63-linked ubiquitin chains from signaling adaptor proteins such as TRAF6 and RIP1, upstream of the Inhibitor of kB kinase (IKK) complex. On the other hand, its E3 ligase domain adds the degradation-inducing K48-linked ubiquitin chains. Thus, A20 potently suppresses NF-kB activity by blocking the ubiquitin-mediated signaling and by promoting the degradation of key factors (Wertz et al., 2004) . DUSPs counteract upon mitogen-activated protein kinase (MAPK) signaling cascades, thereby limiting AP-1 action (Bhattacharyya et al., 2007) . GILZ can bind NF-kB directly and inhibit its activity (Ayroldi et al., 2001) . Most of the genes encoding these factors are known direct targets of GR. Indeed, our GR ChIP-seq analysis of BMDMs reveals that these genes have binding sites which GR can efficiently target even without the chromatin alterations induced by LPS (Figure 7) , in contrast to the vast majority of GR binding sites that show attenuated occupancy without LPS. Altogether, these data suggest that GR transcriptionally activates powerful negative regulators, which target several distinct nodes within the inflammatory signaling cascade, regardless of the changing chromatinscape (over the course of an inflammatory challenge).
DISCUSSION
We have characterized the transcriptomic and epigenomic effects of a late GC treatment by contrasting them against a GC pre-treatment of LPS-stimulated macrophages. It was important to examine the late GC effects because clinical GCs are administered to inflamed tissues as anti-inflammatory interventions. Because a late GC treatment makes GR act upon an inflammatory epigenome, we hypothesized that GR binding may be altered in comparison to a GC pre-treatment where GR encounters a basal chromatin. The binding repertoire of GR has previously been reported to change in HeLa cells in response to stimulation with TNF-a (Rao et al., 2011) and in BMDMs after LPS stimulation (Uhlenhaut et al., 2013) . However, these studies did not examine the immediate genomic binding of GR in the activated versus resting cells, as in this study. In particular, the BMDM study used an overnight pre-treatment of Dex (Uhlenhaut et al., 2013) , which makes it difficult to draw direct comparisons to our data on GR binding immediately after Dex activation. We have characterized the primary GR regulome in cells preactivated with an inflammatory stimulus. GR can only bind to a surprisingly small number of primary target sites in the basal macrophage epigenome and that this limited repertoire dramatically expands if GR is ligand-activated into the ''inflamed chromatinscape.'' An increase of GR occupancy by Dex and LPS co-treatment (versus Dex alone) has been reported previously on a few target sites in BMDMs (Chinenov et al., 2012) . We found that this enlarged GR binding repertoire did not correlate with chromatin modulation or gene regulation. In particular, the enhanced occupancy of GR in LPS-stimulated BMDMs did not correspond to more potent gene repression. Our result argues against the proposed mechanisms of GR gene repression, which involves GR tethering to DNA-bound NF-kB (Reichardt et al., 2001) , direct binding to negative GR responsive elements (nGREs) (Surjit et al., 2011) or recruitment of co-repressors such as GR-interacting protein (GRIP)1 (Chinenov et al., 2012; Uhlenhaut et al., 2013) . It is possible that these processes might occur at some genomic loci in some contexts. However, they are unlikely to be prevalent mechanisms, because a Dex pre-treatment results in very limited GR genomic occupancy in macrophages (which would be expected from either situation) but produces a gene repression program as efficient as a late treatment.
In contrast to GR binding, the genomic occupancy pattern of NF-kB subunit RelA correlated with the observed gene repression in Dex-treated BMDMs. RelA binding was almost entirely abolished in Dex pre-treated cells where GR translocated into the nucleus before NF-kB. In contrast, a previous study using a higher concentration of Dex and an overnight pre-treatment reported a large number of RelA sites in BMDMs (Uhlenhaut et al., 2013) . Since the RelA ChIP intensity from LPS alone was not included in the same experiment, it is difficult to draw any conclusion about Dex-specific changes in RelA binding from that study. According to our direct comparison of NF-kB binding time courses with or without Dex, prevention of RelA binding might be a more likely mechanism for the reduced NF-kB genomic occupancy than an active displacement by GR, although proof is beyond the scope of this study. We should note that prevention of NF-kB (re-)binding to chromatin can produce the observed reduction of occupancy even in Dex late-treated BMDMs, because occupancy measured by ChIP is a snapshot from dynamic transcription factor interactions with chromatin (Hager et al., 2009; Poorey et al., 2013; Sung et al., 2014a; Voss et al., 2011) . The disruption of chromatin-bound RelA by GR is not inconceivable, though, because GR has been reported to bind the DNA binding Rel homology domain of RelA directly (McKay and Cidlowski, 2000) . It will be interesting in the future to determine whether the residual ChIP-seq signal in Dex late-treated BMDMs represents a long-lasting NF-kB occupancy and whether GR can indeed displace RelA from chromatin in living cells. We have considered the possibility that an increased amount of IkBa protein induced by GR in Dex pre-treated cells might block the nuclear translocation of NF-kB. This has been ruled out from likely scenarios, because our live cell imaging analysis of the fluorescent reporter macrophages shows that the nuclear influx of RelA immediately following LPS stimulation is unaffected by Dex pre-treatment.
The differentially timed Dex treatments allowed us to assess whether GR and NF-kB are in a ''race for regulation,'' wherein factors with antagonistic gene programming functions compete for chromatin occupancy and whichever factor arrives at target chromatin first exerts dominant regulatory action. This idea was not supported by our data. Dex pre-treatment activated GR before inflammatory factors, but the small number of GR binding sites before LPS stimulation could not possibly cover all genomic sites that would later be occupied by NF-kB. Moreover, in Dex late-treated cells, GR translocated to the nucleus and encountered chromatinscape already interacting with inflammatory transcription factors, and yet GR could now bind to even more sites. These gained GR binding sites had no particular relationship with respect to the lost RelA binding sites, as virtually all RelA binding sites in the genome were disengaged by Dex treatment. Taken together, these data argue against competition of GR and NF-kB for chromatin binding.
Our data suggest that the so-called ''dissociated ligands'' (Gerstein et al., 2012 ) of GR might not produce the desired therapeutic properties. The rationale behind the search for dissociated ligands was to selectively disable the transactivation by the GR dimer (which was thought to induce side effects of GCs) but to retain the GR monomer tethering to inflammatory transcription factors. First, recent data have largely dismissed the dichotomy of molecular actions between GR monomers versus dimers (Presman et al., 2014) . In fact, a tetramer form of DNA-bound GR has been observed in live cells (Presman et al., 2016) . There is currently little evidence that the anti-inflammatory action of GR comes mostly from the monomer form. Importantly, the ligands that weaken the ability of GR to activate transcription of target genes are likely to impair the induction of the potent inhibitors (such as IkBa and DUSPs) of inflammatory pathways, thereby producing significantly diminished anti-inflammatory effects. Therefore, the function of GR as a transcriptional activator is probably as important for the anti-inflammatory effects of GCs as the widely invoked trans-suppression of NF-kB and AP-1 target genes. Our findings shed light on the multifaceted GR actions upon the ''inflamed epigenome,'' which underlie clinically relevant GC interventions.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: complete Dulbecco's modified Eagle's medium (DMEM, 10% (v/v) fetal bovine serum (FBS)) at 37 C and 5% CO 2 supplemented with 60 ng/ml recombinant mouse M-CSF (R&D). Cells were treated at various time points with 100 nM Dex (Sigma) and/or 10 ng/ml LPS (Alexis Biochemicals, Salmonella minnesota R595 TLRgrade, ALX-581-008-L002). For each assay, cells were preincubated in Hank's balanced salt solution containing 2% FBS (v/v) at 37 C and 5% CO 2 for 2-3 hr before the application of LPS.
METHOD DETAILS
RNA Isolation and Real Time Quantitative RT-PCR Total RNA was isolated from approximately 1x10 6 cells by using an RNAeasy Mini Kit (QIAGEN). Real-time qRT-PCR was performed as previously described (Hakim et al., 2013) . cDNA was synthesized from the extracted 300ng RNA with the iScript cDNA Synthesis Kit (Bio-Rad, 170-8891). qRT-PCR assays were performed with IQ SYBR Green PCR Supermix with an ABI 7900 HT, according to the manufacturer's protocol. Gene expression in each sample was normalized to that of b-actin and fold-changes relative to basal expression were calculated with the 2 ÀDDCt method. Each experiment was performed with three independent repeats. Error bars represent SD of the biological replicates. The following forward and reverse primers spanning consecutive exons were designed to amplify the transcript.
RNA-Seq
RNA was isolated as above from each sample treated with LPS and/or Dex according to the experimental design. Sequencing libraries were generated using Illumina TruSeq V3 protocol and subject to 101 bp paired-end sequencing on Illumina HiSeq2000. Sample quality, library complexity, and alignment statistics were checked using an established pipeline at the NCI Center for Cancer Research Sequencing Facility. All RNA-seq analyses have been performed with two biological replicates. The sequencing reads were aligned against the reference mouse genome mm9 and ensemble v70 transcripts using TopHat (v. 2.0.8). The alignment statistics were greater than 93% for all samples. All short reads were assembled with Cufflinks (v. 2.0.2) with -G option to quantitate against annotated reference transcripts. FPKM data were imported into R for further analyses. All computational analyses were performed on log2 (FPKM + 0.1) values. Transcripts shorter than 200 bp were removed before subsequent analyses. edgeR was used to calculate false discovery rate (FDR) and assess differential gene expression based on FDR < 0.05. LPS-induced genes were defined as the transcripts whose replicate-averaged expression increases by at least 2-fold in at least one time point after LPS stimulation versus basal. For cluster analysis, partitions around the medoids (PAM) algorithm was used after gene-specific centering (to normalize with respect to the basal). Clustering was applied to the average of the biological duplicate expression data for 0h, 4h, 10h LPS, and Dex-pretreated 0h, 4h, 10h LPS samples. Different numbers of clusters were tested to determine the final number of clusters which represent major patterns in the data. Cluster heatmaps were generated displaying all the RNA-seq duplicate data. Genes differentially expressed in the Dex pre-versus late-treated BMDMs (at 10h LPS) were obtained by requiring at least 2-fold difference in the replicate-averaged expression. Gene ontology analysis was performed using the web analysis tool at http://central.biomart.org/enrichment with MGI IDs. Top enriched ontology classes were obtained using the tool VLAD v1.6.0 at http://proto.informatics.jax.org/prototypes/vlad/.
Chromatin Immunoprecipitation
Cells were treated with 10 ng/ml LPS and/or 100 nM Dex for appropriate durations as specified in the experimental design. ChIP assays were performed as described previously (Miranda et al., 2013) with modifications. The following antibodies were used: a mouse monoclonal antibody against GR (MA1-510, Thermo Fisher Scientific) and a rabbit polyclonal anti-RelA antibody (Ab7970, Abcam). For RelA ChIP, BMDMs were subject to crosslinking with 1% formaldehyde for 10 min at room temperature. For GR ChIP, we used a dual crosslinking method (Uhlenhaut et al., 2013) to detect both tethered and directly bound chromatin.
Gene
Forward Reverse
Cx3cr1
CATCTTCCTGTCCGTCTTCTAC GGTAGATGTCAGTGATGCTCTT
Selp
TCTGGTTCAGTGCTTTGATCTC ACAGAACACCCGTGAGTTATTC
Cd55
GTCGAGCCACGAAACATTCT CCACAATAGTACCAACTGGGAAA
Cxcl13
TGTTGTCGGTCTAAACATCATAGA GGCACGAGGATTCACACATA
Clec5a
TCGCTGCACCGAATATCTTATC CGAGATGATCATGTGCCAGTT
Nos2
TGTTCTCAGCCCAACAATACA GTCCAGGGATTCTGGAACATT
Ccl24
CTTGCTGCACGTCCTTTATTT TATGGCCCTTCTTGGTGATG
Mmp13
GTGCCTGATGTGGGTGAATA CAGAATGGGACATATCAGGAGTATAG
Clec7a
TCAGCACTCAAGACATCCATAAA AGCAACCACTACTACCACAAAG
Il12b
CATCTGCTGCTCCACAAGAA TGAACCGTCCGGAGTAATTTG
Beta-actin GCTTCTAGGCGGACTGTTACTGA GCGCAAGTTAGGTTTTGTCAAA
BMDMs were subject to crosslinking with 2mM disuccinimidyl glutarate (DSG) for 30 min followed by 1% formaldehyde for 10 min at room temperature. After crosslinking, chromatin was isolated from about 4 3 10 7 cells, which allows 2 to 3 different immunoprecipitations per sample at a time, and then processed as follows. The lysis buffer to shear the chromatin contained 0.5% SDS, 10 mM EDTA (pH 8), 50 mM tris-HCl (pH 8), and proteinase inhibitor cocktail. Sonication was performed to shear the chromatin to generate DNA fragments with a size range of 400 to 500 base pairs. The sheared chromatin samples were diluted 1:5 in dilution buffer (0.01% SDS, 1.1% Triton-X, 1.2 mM EDTA (pH 8), 20 mM tris-HCl (pH 8), 167 mM NaCl, and proteinase inhibitor cocktail). For each ChIP, 200 mg chromatin DNA was precipitated with antibody coated bead complexes (Dynabeads Protein A for RelA ChIP; anti-IgG paramagnetic beads for GR ChIP, Invitrogen). For ChIP-seq, sequencing libraries were generated using Illumina TruSeq V3 protocol and subject to 51 bp single-end sequencing on Illumina HiSeq2000. Sample quality and library complexity were checked using an established pipeline at the NCI Center for Cancer Research Sequencing Facility. All ChIP-seq analyses have been performed with two or three biological replicates. The ChIP-qPCR assays were performed using biological triplicates. The ChIP products were subjected to qPCR analysis with an IQ SYBR Green Supermix and a MyIQ singlecolor, real-time PCR detection system (Bio-Rad) according to the manufacturers' instructions. DNA mixtures purified from aliquots of each chromatin sample were also subjected to qPCR analysis as input samples, and the results were presented as the ChIP-qPCR measurements normalized to their respective input measurements. The ChIP-qPCR primer sequences are shown below.
DNase-Seq
DNase-seq was performed as previously described Morris et al., 2014) . After treatment with Dex and/or LPS, nuclei of BMDMs were isolated, and chromatin were digested with 80 U/ml DNase I (Sigma) for 3 min at 37 C and incubated at 55 C overnight with 10 mg/ml of RNaseA (Invitrogen) and Proteinase K (Ambion). Digested DNA fragments were purified using phenol-chloroform and enriched by size selection over sucrose gradient. DNA fragments between 100 bp and 500 bp were precipitated and dissolved in nuclease free H 2 O. Two biological replicate samples per treatment group were prepared separately for high throughput sequencing. Sequencing libraries were generated using Illumina TruSeq V3 protocol and subject to 51 bp single-end sequencing on Illumina HiSeq2000. Sample quality and library complexity were checked using an established pipeline at the NCI Center for Cancer Research Sequencing Facility. All DNase-seq assays have been performed with two or three biological replicates.
Sequencing Data Analysis
All sequencing data files were processed and reads were aligned to the mm9 reference genome, using a standardized procedure established for Illumina HiSeq2000 by the NCI Center Cancer Research Sequencing Facility, NIH. The uniquely mapped reads were analyzed to identify regions termed ''hotspots'' using DNase2Hotspots (http://sourceforge.net/projects/ dnase2hotspots) (Baek and Sung, 2016; Baek et al., 2012) . All the ChIP-seq and DNase-seq hotspots were compiled into a master set of genomic regions for integrative analysis. The region boundaries were determined as the union of all overlapping hotspots. For quantifying the signal intensity (termed density) of ChIP-seq or DNase-seq over each region in the master set, we used ''AveD,'' the count of overlapping fragments averaged over the region (Baek and Sung, 2016; Baek et al., 2012) . For the GR dual crosslinking ChIP-seq data, we applied a density-based threshold to remove small noisy hotspots before calculating the number of binding sites. The midpoint between the two Gaussian distributions of maximum density values was chosen to be the threshold. For calculating the distances between GR and RelA binding sites, GR hotspots were AveD-thresholded at 50 percentile observed for the late Dex treatment, and RelA were AveD-thresholded at 50 percentile observed for 3h LPS. The density-based thresholding removed small low-confidence hotspots that may be unreliable.
Area-proportional Venn diagrams showing factor binding sites were drawn using EulerAPE v3 available at http://www. eulerdiagrams.org/eulerAPE (Micallef and Rodgers, 2014) .
Motif discovery analysis was performed using MEME and Tomtom (Bailey et al., 2015) . For querying against a database of known TF binding specificity, we used CisBP (Weirauch et al., 2014 Live Cell Imaging and Quantification Time lapse microscopy of live RAW264.7 reporter clone was performed as described (Sung et al., 2014b ) using a Zeiss LSM 880 equipped with a controlled incubation chamber (37 C, humidified 5% CO 2 ). Cells were treated with LPS with or without Dex preor late-treatment onstage through separate injection tubing for LPS and Dex. The timing of Dex treatments was identical to that for the ChIP-seq experimental design. Time lapse images were acquired at 8 min intervals with two sequential frames for EGFP and mCherry for each stage position with 0.3% of power for both 488nm and 561nm laser lines, using Plan-Apochromat 40 3 oil objective (1.4 NA), zoom 1, 512 by 512 pixels, no averaging, maximally open pinhole, ''Definite Focus'' autofocus, and the GaAsP spectral detector. The 16 bit raw TIFF imaging data were analyzed and quantified using previously developed custom MATLAB codes (Sung et al., 2014b) with slight modifications to match the current acquisition parameters.
Western Blotting
Whole-cell extracts and nuclear extracts from 1x10 7 BMDM cells per condition were prepared in RIPA cell lysis buffer (Millipore, and NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Sci 78833), respectively. 40 mg of protein were denatured with 2 3 SDS-PAGE sample buffer (Quality Biological, 351-082-661) at 85 C for 5 min. 25 ml of protein was resolved with an 8 to 16% Tris-Glycine SDS Gel (Invitrogen, XP08162)/Tris-Glycine Running Buffer System (Invitrogen, LC2675) and transferred to nitrocellulose membranes. The membranes were analyzed by western blotting according to a standard protocol. The antibodies used are as follows: rabbit anti-p65 (Santa Cruz, sc-372), rabbit anti-IkBa (Santa Cruz, sc-371), rabbit anti-STAT3 (Santa Cruz, sc-482), rabbit anti-p38 MAPK (Cell Signaling, 9212L), rabbit anti-phospho p38 MAPK (Cell Signaling, 4511S), rabbit anti-ERK2 (Santa Cruz, sc-154), rabbit anti-Rho-GDI (Sigma, R3025), rabbit anti-phospho ERK1/2 (Cell Signaling, 9101), rabbit anti-hnRNP (Santa Cruz, sc-28726), and HRP-conjugated ECL anti-rabbit immunoglobulin G (GE Healthcare).
QUANTIFICATION AND STATISTICAL ANALYSIS
Software, quantification, and computational methods are described in the relevant method sections above.
DATA AND SOFTWARE AVAILABILITY
All data have been deposited in the GEO database at https://www.ncbi.nlm.nih.gov/geo/ in the SuperSeries with accession number GSE93739.
